Am I at Risk of Liver Disease? A Self-Check to Measure Your Liver Disease Risk
Liver disease is silent until late, so ask about risk, not symptoms. Diabetes, a waist over 90 cm in men or 80 cm in women, alcohol, hepatitis B or C exposure, and cirrhosis in a parent or sibling each raise it. A FIB-4 score below 1.3, calculated from age, AST, ALT and platelets, makes advanced scarring unlikely; above that, ask for a FibroScan.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai
Key takeaways
- The liver does not hurt. Most cirrhosis is found in someone who felt well, so risk — not symptoms — is what to check.
- Five things do most of the damage in India: type 2 diabetes, a large waist (90 cm in men, 80 cm in women at Asian cut-offs), alcohol, hepatitis B or C, and a first-degree relative with cirrhosis or liver cancer.
- FIB-4 turns four routine numbers — age, AST, ALT, platelet count — into an estimate of scarring. Below 1.3 (2.0 if you are over 65) advanced fibrosis is unlikely; above 2.67 it is likely; in between, a FibroScan settles it.
- Everyone with type 2 diabetes, and anyone with abdominal obesity plus one more metabolic problem, should have a FIB-4 even when the liver function test is normal. EASL 2024 and AASLD 2023 both say so.
- One HBsAg and one anti-HCV test, once, for anyone transfused in India before June 2001, born to a mother with hepatitis B, or exposed in a household or through unsafe injections. Hepatitis C is now curable in over 95% of people.
- A self-check is not a diagnosis. Its job is to tell you which test to ask for next.
A composite of a patient I see most weeks. A 54-year-old schoolteacher from Dadar has had type 2 diabetes for nine years. Her weight is “normal” — BMI 24 — but her waist measures 92 cm. Her yearly liver function test has always been normal; nobody has mentioned her liver. Her mother died of a “liver problem” at seventy, and no one in the family drinks. When I put her age, AST, ALT and platelet count into the FIB-4 formula the score comes to 2.1. A FibroScan reads 11.4 kPa. Advanced fibrosis — found not by a symptom but by a question about risk.
Liver disease is quiet for twenty years and then loud for two, and by the time jaundice, ascites or a bleed arrives the chance to reverse course has mostly gone. My post on the signs of liver damage covers late disease; this one is about the stage before, when there is nothing to feel and everything to gain. Below: the self-check, FIB-4 in plain language, and who needs a FibroScan or a hepatitis test. It is educational decision support, not a diagnosis — its job is to send you into a clinic with a specific request.
The self-check: ten questions about your liver disease risk
Answer honestly. Each “yes” is a reason to act, not a verdict, and the groups matter more than the count — there is no validated point-score here, and I will not invent one.
Metabolic
- Do you have type 2 diabetes, or prediabetes (HbA1c 5.7% or above, or fasting glucose 100–125 mg/dL)?
- Is your waist 90 cm or more (men) or 80 cm or more (women)? Measure midway between the lowest rib and the top of the hip bone, at the end of a normal breath out.
- Is your BMI 23 or more? That is the Asian cut-off for overweight; the Western charts say 25, and they under-call risk in Indians.
- Have you been told you have high triglycerides, low HDL or high blood pressure — or has any ultrasound ever reported “fatty liver” or “grade 1 or 2 fatty infiltration”?
Alcohol
- Do you drink on most days, or more than roughly 14 drinks a week if you are a man and 7 if you are a woman?
Exposure to hepatitis B or C
- Did you receive a blood transfusion or blood products in India before June 2001? Hepatitis C screening of donated blood became mandatory only then.
- Was your mother hepatitis B positive, or is a household member or sexual partner — or do you have no record of ever being vaccinated against hepatitis B?
- Have you ever had an injection with a reused needle, a tattoo or piercing in an unregulated setting, or injected drugs?
Family, supplements and age
- Has a parent, sibling or child had cirrhosis or liver cancer?
- Do you regularly take herbal, ayurvedic or bodybuilding products — Giloy, kadha, “liver tonics”, anabolic steroids — or are you a man over 50 or a woman past menopause?
What to do with the answers. A yes in the metabolic group means a FIB-4 — most people already have the four numbers from a routine blood panel. A yes to alcohol means the same, plus an honest drinking history for whoever interprets it. A yes in the exposure group means a one-time HBsAg and anti-HCV test, whatever your enzymes show. A yes in the last group does not change which test you need; it lowers the threshold at which an abnormal result should be taken seriously, and it is why a normal-weight person with a family history still belongs in a liver clinic.
What each risk factor does to the liver, and the test to ask for
The reasoning behind each question is in the table. Two threads run through it: fat and sugar scar the liver through inflammation, and in Indians they do so at a lower body weight than Western charts expect; viruses scar it through decades of silent replication, and the people who carry them in India are mostly the ones never tested.
| Risk factor | Why it matters | What test to ask for |
|---|---|---|
| Type 2 diabetes or prediabetes | EASL 2024 names diabetes and abdominal obesity as the two metabolic diseases with the strongest effect on progression to advanced fibrosis, cirrhosis and liver cancer. Roughly 39% of Indian adults have fatty liver, and the proportion in high-risk groups such as diabetics is over half. | FIB-4 from a routine panel (AST, ALT, platelet count). Every guideline now asks for fibrosis case-finding in all people with type 2 diabetes. See fatty liver and diabetes. |
| Waist ≥90 cm (men) / ≥80 cm (women); BMI ≥23 | Visceral fat, not total weight, carries the liver risk. The MASLD definition uses 90/80 cm for South Asians and BMI 23 for Asian ethnicity, because risk in our population starts well below the Western 94 cm / BMI 25. | FIB-4 if the waist cut-off is met together with one more metabolic factor (raised sugar, triglycerides, low HDL, hypertension). |
| Alcohol | Alcohol and metabolic risk multiply rather than add. In overweight men, liver-related mortality rises from about 30 g of alcohol a day; the global burden analysis found the intake that minimises overall harm is zero. | FIB-4 and a liver panel; GGT and an honest units-per-week history. Any fibrosis means complete, permanent abstinence. |
| Hepatitis B exposure — mother HBsAg-positive, household or sexual contact, unsafe injections, transfusion before 1996, no vaccination record | Infection acquired at birth or in childhood almost always becomes lifelong and can progress to cirrhosis and cancer with normal enzymes for decades. About 0.85% of Indians — roughly one in 118 — carry the virus, most unknowingly. | HBsAg once; if negative and unvaccinated, anti-HBs and vaccination. If positive, see who needs hepatitis B treatment. |
| Hepatitis C exposure — transfusion or blood products before June 2001, reused needles, dialysis, tattoos, injecting drug use | Chronic hepatitis C causes slow fibrosis over 20–30 years and is curable in more than 95% of people with 12 weeks of tablets. Prevalence in India is about 0.29%. | Anti-HCV antibody once; HCV RNA if positive. Free under the national programme. |
| First-degree relative with cirrhosis or liver cancer | First-degree relatives of people with fatty-liver cirrhosis had advanced fibrosis in 17.9% versus 1.4% of controls — a twelve-fold risk after adjustment. A family history of liver cancer also lowers the threshold for cancer surveillance in hepatitis B. | FIB-4 and, if any doubt, a FibroScan directly; HBsAg if the relative’s disease was viral. |
| Herbal, ayurvedic and bodybuilding supplements | A 13-centre Indian study during COVID-19 documented 43 cases of Giloy-related liver injury, median 46 days after starting, several with autoimmune features and some presenting as liver failure. EASL 2024 recommends against nutraceuticals in fatty liver for lack of evidence of benefit or safety. | Liver function test now and six weeks after stopping; tell the doctor exactly what you take, by brand. |
| Age — men over 50, post-menopausal women, anyone over 65 | The ageing liver mounts a stronger fibrotic response to the same injury and tolerates it less well. Age is also a term in the FIB-4 formula, which is why the over-65 cut-off is higher. | The same tests, read with the age-adjusted FIB-4 threshold (2.0, not 1.3). |
FIB-4 explained: a scarring estimate from four numbers you probably already have
FIB-4 was built in 2006 from 832 patients with HIV and hepatitis C, as a cheap way to avoid biopsies. It has since been validated in fatty liver disease, alcohol and hepatitis B, and both EASL 2024 and AASLD 2023 make it the first step in checking for fibrosis — ahead of ultrasound, ahead of the liver function test, ahead of referral.
The formula is: age (years) × AST (U/L), divided by platelet count (×10⁹/L) × √ALT (U/L). Each piece says something. Age stands in for how long the liver has been exposed. AST leaks from stressed liver cells and, as scarring advances, climbs relative to ALT, so a high AST with a modest ALT pushes the score up. Platelets fall as the scarred liver raises portal pressure and the spleen traps them. A high score, then, is an older liver with enzyme stress and falling platelets.
Take the schoolteacher from the opening: age 54, AST 41, ALT 36, platelets 172. Fifty-four times 41 is 2,214. The square root of 36 is 6, and 172 × 6 is 1,032. Divide: 2,214 ÷ 1,032 = 2.1.
How to read the result, using the cut-offs both guidelines share:
- Below 1.3 — advanced fibrosis is unlikely. Manage the risk factors, repeat in one to three years.
- 1.3 to 2.67 — indeterminate. Go to a FibroScan, particularly if the score is near 2.67, you have diabetes, or there is a family history. EASL allows an alternative: a year of lifestyle change, then repeat the score.
- Above 2.67 — advanced fibrosis is likely. Hepatology referral, with a FibroScan on the way.
- Over 65? Use 2.0 as the lower cut-off instead of 1.3. Age inflates the score, and in a European cohort the standard threshold produced false positives in two-thirds of people over 65; raising it to 2.0 restored specificity to 70% without losing sensitivity.
Three honest limits. FIB-4 misses about one in ten people with advanced fibrosis — EASL says so in as many words — so a low score in long-standing diabetes should not end the conversation. It performs poorly under 35. And it is a fibrosis estimate, not a liver test: in acute hepatitis, after a binge, or when platelets are low for another reason, the number means little. Used in the right person, though, it is remarkable — an individual-patient meta-analysis of 2,518 biopsy-proven cases found FIB-4 predicted liver-related outcomes about as well as the biopsy itself. If the four numbers are in a report at home, calculate it tonight; my guide to the LFT normal range explains the rest of that report.
Who needs a FibroScan next
Anyone whose FIB-4 is 1.3 or above (2.0 or above over 65), anyone with a score above 2.67, and — in my practice — anyone with type 2 diabetes for more than ten years or a first-degree relative with cirrhosis, regardless of the score, because those are the people in whom FIB-4 is least reliable and the stakes highest.
FibroScan measures liver stiffness in kilopascals. The EASL thresholds are simple: below 8 kPa rules out advanced fibrosis; 12 kPa or above rules it in; between the two is a grey zone that needs a hepatologist and sometimes a second test. The whole thing takes ten minutes, needs no needles, and is done in the OPD. I have written separately on FibroScan versus liver biopsy and on what the report means, in Hindi; the FibroScan service page covers how to book one in Mumbai.
One warning for the diabetic reader. A normal ultrasound is not reassurance: ultrasound sees fat, not scar, and a liver approaching cirrhosis can look less fatty as the fat burns out. The sequence is blood score, then stiffness — not scan, then shrug.
Who should be tested for hepatitis B and C
India sits below the 2% hepatitis B prevalence at which the WHO recommends testing every adult — the 2021 sentinel surveillance put HBsAg at 0.85% and anti-HCV at 0.29% — so testing here is targeted, and the target list is the exposure group of the self-check. WHO and India’s National Viral Hepatitis Control Programme between them name: every pregnant woman (universal in India’s antenatal programme); anyone with suspected liver disease or abnormal enzymes; blood donors; household and sexual contacts of someone infected; children of a hepatitis B-positive mother, at any age; healthcare workers; people who inject drugs; people living with HIV; people in prisons; men who have sex with men, sex workers and transgender people.
Two Indian-specific items belong on that list. First, transfusion. Blood banks were not required to screen for hepatitis C until 1 June 2001, so anyone transfused before that — surgery, childbirth, thalassaemia, an accident — has an exposure that was never checked. Second, mothers. Hepatitis B in India is still mostly acquired at birth, so if your mother is or was HBsAg-positive, every sibling needs a test, not just the one who fell ill.
The testing is one blood draw — HBsAg and anti-HCV — and under the national programme both the tests and the drugs are free at designated government centres; the helpline 1800-11-6666 will direct you. A positive hepatitis C result today is close to good news: direct-acting antivirals cure more than 95% of people in 12 to 24 weeks. A positive hepatitis B result is a chronic condition to be managed, not a sentence; which patients need tablets is a separate decision I have covered in hepatitis B treatment in India. If you are unsure which virus is which, start with hepatitis B versus hepatitis C or the broader guide to the five hepatitis viruses.
Prevention — and a word about the ageing liver
Vaccinate. The hepatitis B vaccine is three doses, protects for at least twenty years and probably for life, and if you have no record of it an anti-HBs test will tell you whether you need it. Hepatitis A vaccine is recommended for anyone with an existing chronic liver condition — hepatitis B or C, cirrhosis, fatty liver — because hepatitis A on a damaged liver can be severe; many Indian adults are already immune from childhood exposure, so in my practice an IgG anti-HAV test comes first.
On alcohol, I will not give you a safe number, because there is not one. The Global Burden of Disease analysis of 195 countries concluded that the level of drinking that minimises overall health loss is zero, and EASL 2024 states that emerging evidence does not support a protective effect of light or moderate drinking, least of all with metabolic risk. Where the liver data get loud: in overweight men, liver-related death rises from around 30 g of alcohol a day — about three 30 ml pegs of spirit. Fatty liver: drink less or not at all. Any fibrosis: stop completely and permanently. That is the guideline wording, and mine.
On weight, the targets are specific. A sustained loss of 5% of body weight reduces liver fat, 7–10% calms the inflammation, and 10% or more improves fibrosis. On supplements, the rule is simpler: nothing sold as a liver tonic has been shown to help the liver, and several have been shown to hurt it. Bring the bottles to the consultation.
Finally, age. Men over 50 and women past menopause are at higher risk of progressive fibrosis in fatty liver disease, and the liver over 65 responds to the same insult — alcohol, fat, a drug — with more scarring and less reserve. None of this means an older person should be screened less; it means the numbers need reading differently, which is why FIB-4 has a separate cut-off after 65 and why a borderline FibroScan in a 70-year-old deserves a hepatologist rather than wait-and-see.
Our liver clinic in Mumbai does this assessment in a single visit — history, waist, FIB-4 from your existing reports, FibroScan, and the two hepatitis tests if the exposure questions apply. But the first step costs nothing and needs no appointment: a tape measure, the last blood report in the drawer, and an honest answer to question five.
Frequently asked questions
Can I have liver disease if my liver function test is normal?
Yes. A normal ALT and AST does not exclude significant fibrosis or even cirrhosis, especially in fatty liver disease and chronic hepatitis B. That is why the guidelines ask for a fibrosis score such as FIB-4 in everyone with type 2 diabetes or abdominal obesity, rather than relying on the liver function test alone.
What is a normal FIB-4 score?
Below 1.3 makes advanced fibrosis unlikely; above 2.67 makes it likely; between the two is indeterminate and should lead to a FibroScan. If you are over 65, use 2.0 instead of 1.3 as the lower cut-off, because age itself raises the score.
Who should get a FibroScan?
Anyone with a FIB-4 of 1.3 or more (2.0 or more if over 65), anyone with a score above 2.67, and people at very high risk — long-standing type 2 diabetes or a first-degree relative with cirrhosis — regardless of the score. A liver stiffness below 8 kPa rules out advanced fibrosis; 12 kPa or more rules it in.
Who should be tested for hepatitis B and C in India?
Every pregnant woman; anyone transfused before June 2001; children, household members and sexual partners of a hepatitis B-positive person; people who have had unsafe injections, tattoos or injecting drug use; healthcare workers; people living with HIV; and anyone with abnormal liver enzymes or suspected liver disease. One HBsAg and one anti-HCV test, once, is enough to know. Both tests and treatment are free under the National Viral Hepatitis Control Programme.
Is any amount of alcohol safe for the liver?
No amount is beneficial. The Global Burden of Disease analysis found the intake that minimises overall harm is zero, and EASL 2024 does not support a protective effect of light drinking. Risk rises steeply with quantity and is multiplied by obesity or diabetes. Anyone with fatty liver should cut down or stop; anyone with fibrosis should stop completely and permanently.
Does a family history of liver disease matter if I do not drink?
Yes. First-degree relatives of people with fatty-liver cirrhosis have about a twelve-fold higher risk of advanced fibrosis even after adjusting for weight and diabetes, and a family history of liver cancer lowers the threshold for cancer surveillance in hepatitis B. If a parent or sibling had cirrhosis or liver cancer, ask for a FIB-4 and, if there is any doubt, a FibroScan.
Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.
References
- European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. PMID 38851997. doi:10.1016/j.jhep.2024.04.031 (open-access co-publication: Obes Facts. 2024;17(4):374–444. PMID 38852583)
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. PMID 36727674. doi:10.1097/HEP.0000000000000323
- Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. PMID 16729309. doi:10.1002/hep.21178
- McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–751. PMID 27725647. doi:10.1038/ajg.2016.453
- Mózes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(8):704–713. PMID 37290471. doi:10.1016/S2468-1253(23)00141-3
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163. PMID 14726171. doi:10.1016/S0140-6736(03)15268-3
- Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. PMID 37363821. doi:10.1097/HEP.0000000000000520
- Shalimar, Elhence A, Bansal B, et al. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. J Clin Exp Hepatol. 2022;12(3):818–829. PMID 35677499. doi:10.1016/j.jceh.2021.11.010
- Caussy C, Soni M, Cui J, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest. 2017;127(7):2697–2704. PMID 28628033. doi:10.1172/JCI93465
- GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015–1035. PMID 30146330. doi:10.1016/S0140-6736(18)31310-2
- Kulkarni AV, Hanchanale P, Prakash V, Kalal C, et al. Tinospora cordifolia (Giloy)-induced liver injury during the COVID-19 pandemic — multicenter nationwide study from India. Hepatol Commun. 2022;6(6):1289–1300. PMID 35037744. doi:10.1002/hep4.1904
- Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31(3):184–191. PMID 25850346. doi:10.1097/MOG.0000000000000176
- Mishra D, Pensi T. Transfusion associated hepatitis C in multi-transfused thalassemic children. Indian Pediatr. 2004;41(3):287–288. PMID 15064522.
- Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. PMID 29405329. doi:10.1002/hep.29800
- Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69(5):1–38. PMID 32614811. doi:10.15585/mmwr.rr6905a1
- World Health Organization. Hepatitis B fact sheet. 28 July 2026. who.int/news-room/fact-sheets/detail/hepatitis-b
- World Health Organization. Hepatitis C fact sheet. 28 July 2026. who.int/news-room/fact-sheets/detail/hepatitis-c
- Press Information Bureau, Government of India. India’s fight to combat hepatitis (National Viral Hepatitis Control Programme backgrounder). 27 July 2026. static.pib.gov.in (PDF)
